Published in Surg Neurol Int on February 13, 2015
Distribution of polymer nanoparticles by convection-enhanced delivery to brain tumors. J Control Release (2016) 0.79
The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics. Oncogene (2015) 0.79
Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer. Ther Deliv (2015) 0.76
Convection-Enhanced Delivery. Neurotherapeutics (2017) 0.75
Convection-enhanced Delivery of Therapeutics for Malignant Gliomas. Neurol Med Chir (Tokyo) (2016) 0.75
Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst (1993) 7.87
Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A (1994) 6.61
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol (2002) 4.50
Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng (1999) 3.64
Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med (1997) 2.76
P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev (1999) 2.34
Hindered diffusion of high molecular weight compounds in brain extracellular microenvironment measured with integrative optical imaging. Biophys J (1993) 2.32
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg (2005) 2.07
Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol (2010) 2.04
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol (2007) 2.01
High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol (1994) 2.01
Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg (1995) 1.94
Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol (2000) 1.80
EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res (2010) 1.79
Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg (2002) 1.79
Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics (2008) 1.79
Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg (2004) 1.78
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol (2010) 1.78
Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc (2005) 1.74
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery (2007) 1.74
Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus (2006) 1.61
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
Direct convective delivery of macromolecules to the spinal cord. J Neurosurg (1998) 1.53
Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg (2007) 1.51
Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol (2003) 1.50
Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol (2003) 1.46
Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg (2008) 1.40
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol (2007) 1.39
Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res (2005) 1.38
Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res (2005) 1.35
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol (2010) 1.30
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery (2007) 1.27
Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol (2003) 1.26
Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg (2008) 1.25
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg (2007) 1.24
Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery (1996) 1.19
Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol (2005) 1.16
Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. AJR Am J Roentgenol (2007) 1.16
Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery (2011) 1.14
Interstitial fluid flow along white matter tracts: a potentially important mechanism for the dissemination of primary brain tumors. J Neurooncol (1997) 1.12
Prediction of convection-enhanced drug delivery to the human brain. J Theor Biol (2007) 1.09
Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery (2011) 1.08
Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res (2011) 1.07
Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res (1995) 1.05
Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery (2005) 1.04
Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neuro Oncol (2004) 1.01
Transport of cisplatin in rat brain following microinfusion: an analysis. J Pharm Sci (1986) 0.98
Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl (2003) 0.98
The delivery of BCNU to brain tumors. J Control Release (1999) 0.95
Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles. Int J Nanomedicine (2011) 0.93
Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol (2012) 0.92
Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine (2013) 0.91
Specificity and mobility of biomacromolecular, multivalent constructs for cellular targeting. Biomacromolecules (2007) 0.89
Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol (2010) 0.89
Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery. Cancer Gene Ther (2011) 0.89
New approach to tumor therapy for inoperable areas of the brain: chronic intraparenchymal drug delivery. J Neurooncol (2002) 0.88
A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme. Contemp Clin Trials (2011) 0.88
Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother (1997) 0.88
Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. J Neurosurg Pediatr (2012) 0.86
Targeted drug delivery for treatment and imaging of glioblastoma multiforme. Expert Opin Drug Deliv (2009) 0.86
Local chemotherapy in the rat brainstem with multiple catheters: a feasibility study. Childs Nerv Syst (2008) 0.82
Convection-enhanced delivery of targeted toxins for malignant glioma. Expert Opin Drug Deliv (2006) 0.82
Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues. J Neurosci Methods (2004) 0.81
Toxicity and cerebrospinal fluid levels of carboplatin chronically infused into the brainstem of a primate. J Neurooncol (2004) 0.81
Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model. J Neurooncol (1998) 0.81
Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring. J Pharmacol Exp Ther (2009) 0.81
Convection-enhanced delivery of AAV2 in white matter--a novel method for gene delivery to cerebral cortex. J Neurosci Methods (2013) 0.80
Stereotactic administration of intratumoral chronic chemotherapy of recurrent malignant gliomas. Appl Neurophysiol (1987) 0.79
Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride. J Neurosurg Pediatr (2011) 0.79
Convection-enhanced delivery catheter placements for high-grade gliomas: complications and pitfalls. J Neurooncol (2011) 0.78